Opiant Pharmaceuticals (OPNT), Adapt Pharma Operations, Adapt Pharma Inc. and Adapt Pharma Ltd. initiated patent litigation on October 25 in the District Court for the District of New Jersey regarding Perrigo’s (PRGO) Paragraph IV Abbreviated New Drug Application for naloxone hydrochloride nasal spray 4mg, asserting patents listed in the Orange Book for Narcan. This action formally initiates the litigation process. Narcan Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Annual market sales for the 12 months ending August 2018 were $95M..
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.